88 results
Page 2 of 5
8-K
EX-99.2
nyz 3ch1q9r3g8ce
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
9u1 krvk83
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.2
iy7cv
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
DFAN14A
EX-99.1
d385ogqqf1kicyet
25 Apr 22
Additional proxy materials by non-management
3:31pm
DFAN14A
EX-99.5
n9va4td9 itur
22 Apr 22
Additional proxy materials by non-management
10:07am
DFAN14A
EX-99.4
9d03p s7mkbnq
22 Apr 22
Additional proxy materials by non-management
10:07am
DEFA14A
bckrvy
11 Apr 22
Additional proxy soliciting materials
4:36pm
DEFC14A
s1jza4xcksg9 sf
5 Apr 22
Proxy in contested solicitation
4:08pm
PREC14A
ddknc9f
25 Mar 22
Preliminary proxy with contested solicitation
5:15pm
8-K
3vbembld7q2
31 Jan 22
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
4:15pm
8-K
EX-10.1
anbg5u8u0n1 4cu
31 Jan 22
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
4:15pm
8-K
EX-10.2
23rfe 1jp
31 Jan 22
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
4:15pm
S-3
EX-4.3
k9iryodjp
15 Nov 21
Shelf registration
4:06pm
S-3
thz3itclaq
15 Nov 21
Shelf registration
4:06pm
S-3
EX-5.1
mfmqbtfg
15 Nov 21
Shelf registration
4:06pm